Summary

What is the most appropriate treatment of acute hypertensive response after intracerebral hemorrhage? Over time, two schools of thought have emerged: one that thinks blood pressure should not be treated because hematoma expansion is uncommon and perihematoma ischemia is a concern, and one that takes the opposite position. The goal of the open-label Antihypertensive Treatment of Acute Cerebral Hemorrhage trial [ATACH] was to determine the tolerability and safety of three different systolic blood pressure goals using IV nicardipine.